Diffuse Large B-Cell Lymphoma Prognosis (R-IPI)

Determine prognosis in diffuse large B-cell lymphoma


The original International Prognostic Index (IPI) was developed and validated prior to the addition of rituximab to curative anthracycline-based chemotherapy. Clinical trials have confirmed that rituximab improves the survival of individuals with diffuse large B-cell lymphoma.

The revised International Prognostic Index (R-IPI) was developed to predict the outcome of individuals receiving rituximab with chemotherapy. The score is able to differentiate patients into three groups (very good, good, poor), all of who have survival >50% in the new era.


The original IPI was developed by Shipp et al.

A predictive model for aggressive non-Hodgkin's lymphoma.

New England Journal of Medicine 1993 September 30, 329 (14): 987-94

The Diffuse Large B-Cell Lymphoma Prognosis (R-IPI) calculator is created by QxMD.

Created by on 02/01/2016

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Age?

0/5 completed